Akebia expects to file vadadustat again to FDA by end of Q3; Societal CDMO seeks to secure 8M+ in latest raise

Ake­bia now ex­pects to re­file its chron­ic kid­ney dis­ease treat­ment vadadu­s­tat by the end of Sep­tem­ber.

The biotech said Thurs­day morn­ing that it had a Type A meet­ing with reg­u­la­tors last month.

The FDA re­ject­ed the com­pa­ny’s lead can­di­date for pa­tients with ane­mia due to chron­ic kid­ney dis­ease back in March 2022 over safe­ty con­cerns, and in May, Ake­bia said it would re­file some­time in the sec­ond half of 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.